SHORT MINI FUTURE - MODERNA | Real-time Bid/Ask 06:03:06 2024-05-23 am EDT | ||
| 0.42 CHF / 0.43 CHF | -7.61% |
|
| Current month | -47.13% | ||
| 1 month | -51.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 0.46 | -25.81% |
| 24-05-21 | 0.62 | -10.14% |
| 24-05-17 | 0.69 | -1.43% |
| 24-05-16 | 0.7 | -4.11% |
| 24-05-15 | 0.73 | +1.39% |
Delayed Quote Swiss Exchange
Last update May 22, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| LMRFJB | |
| ISIN | CH1242790447 |
| Date issued | 2023-02-02 |
| Strike | 204.2 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.23 CHF |
|---|---|
| Lowest since issue | 0.27 CHF |
| Spread | 0.01 CHF |
| Spread % | 2.38% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Certificates
- LMRFJB Certificat
